Regulation of PD-L1 expression in the tumor microenvironment

被引：450

作者：

Yi, Ming ^{[1
]}

Niu, Mengke ^{[1
,2
,3
]}

Xu, Linping ^{[2
,3
]}

Luo, Suxia ^{[2
,3
]}

Wu, Kongming ^{[1
,2
,3
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Oncol, Tongji Hosp, Wuhan 430030, Peoples R China

[2] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China

[3] Henan Canc Hosp, Zhengzhou 450008, Peoples R China

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2021年 / 14卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Cancer immunology; PD-L1; PD-1; Transcriptional regulation; Post-transcriptional modification; PROMOTES ANTITUMOR IMMUNITY; SQUAMOUS-CELL CARCINOMA; PD-LL EXPRESSION; NF-KAPPA-B; LUNG-CANCER; UP-REGULATION; TNF-ALPHA; TGF-BETA; SIGNALING PATHWAYS; DENDRITIC CELLS;

D O I：

10.1186/s13045-020-01027-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and eradicate cancer cells. However, only a subset of PD-L1 positive patients benefits from alpha-PD-1/PD-L1 therapies. Actually, PD-L1 expression is regulated by various factors, leading to the diverse significances of PD-L1 positivity. Understanding the mechanisms of PD-L1 regulation is helpful to select patients and enhance the treatment effect. In this review, we focused on PD-L1 regulators at the levels of transcription, post-transcription, post-translation. Besides, we discussed the potential applications of these laboratory findings in the clinic.

引用

页数：13

共 153 条

[51] BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1 [J].

Hogg, Simon J. ;

Vervoort, Stephin J. ;

Deswal, Sumit ;

Ott, Christopher J. ;

Li, Jason ;

Cluse, Leonie A. ;

Beavis, Paul A. ;

Darcy, Phillip K. ;

Martin, Benjamin P. ;

Spencer, Andrew ;

Traunbauer, Anna K. ;

Sadovnik, Irina ;

Bauer, Karin ;

Valent, Peter ;

Bradner, James E. ;

Zuber, Johannes ;

Shortt, Jake ;

Johnstone, Ricky W. .

CELL REPORTS, 2017, 18 (09) :2162-2174

[52] Is H3K4me3 instructive for transcription activation [J].

Howe, Francoise S. ;

Fischl, Harry ;

Murray, Struan C. ;

Mellor, Jane .

BIOESSAYS, 2017, 39 (01) :1-12

[53] STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion [J].

Hsu, Jung-Mao ;

Xia, Weiya ;

Hsu, Yi-Hsin ;

Chan, Li-Chuan ;

Yu, Wen-Hsuan ;

Cha, Jong-Ho ;

Chen, Chun-Te ;

Liao, Hsin-Wei ;

Kuo, Chu-Wei ;

Khoo, Kay-Hooi ;

Hsu, Jennifer L. ;

Li, Chia-Wei ;

Lim, Seung-Oe ;

Chang, Shih-Shin ;

Chen, Yi-Chun ;

Ren, Guo-Xin ;

Hung, Mien-Chie .

NATURE COMMUNICATIONS, 2018, 9

[54] NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer [J].

Huang, Tung-Yung ;

Chang, Tung-Cheng ;

Chin, Yu-Tang ;

Pan, Yi-Shin ;

Chang, Wong-Jin ;

Liu, Feng-Cheng ;

Hastuti, Ema Dwi ;

Chiu, Shih-Jiuan ;

Wang, Shwu-Huey ;

Changou, Chun A. ;

Li, Zi-Lin ;

Chen, Yi-Ru ;

Chu, Hung-Ru ;

Shih, Ya-Jung ;

Cheng, R. Holland ;

Wu, Alexander ;

Lin, Hung-Yun ;

Wang, Kuan ;

Whang-Peng, Jacqueline ;

Mousa, Shaker A. ;

Davis, Paul J. .

CELLS, 2020, 9 (08)

[55] PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer [J].

Ikeda, Seiichi ;

Okamoto, Tatsuro ;

Okano, Shinji ;

Umemoto, Yuichiro ;

Tagawa, Tetsuzo ;

Morodomi, Yosuke ;

Kohno, Mikihiro ;

Shimamatsu, Shinichiro ;

Kitahara, Hirokazu ;

Suzuki, Yuzo ;

Fujishita, Takatoshi ;

Maehara, Yoshihiko .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) :62-71

[56] miR-142-5p regulates tumor cell PD-Ll expression and enhances anti-tumor immunity [J].

Jia, Long ;

Xi, Qing ;

Wang, Huafeng ;

Zhang, Zimu ;

Liu, Hongkun ;

Cheng, Yingnan ;

Guo, Xiangdong ;

Zhang, Jieyou ;

Zhang, Qi ;

Zhang, Lijuan ;

Xue, Zhenyi ;

Li, Yan ;

Da, Yurong ;

Zhao, Peng ;

Zhang, Rongxin .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 488 (02) :425-431

[57] Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-Ll expression on tumor-associated macrophages [J].

Jiang, Canhua ;

Yuan, Fulai ;

Wang, Jie ;

Wu, Limeng .

IMMUNOBIOLOGY, 2017, 222 (04) :651-657

[58] Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape [J].

Jiang, Xianjie ;

Wang, Jie ;

Deng, Xiangying ;

Xiong, Fang ;

Ge, Junshang ;

Xiang, Bo ;

Wu, Xu ;

Ma, Jian ;

Zhou, Ming ;

Li, Xiaoling ;

Li, Yong ;

Li, Guiyuan ;

Xiong, Wei ;

Guo, Can ;

Zeng, Zhaoyang .

MOLECULAR CANCER, 2019, 18 (1)

[59] The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition [J].

Jiang, Xiaofeng ;

Zhou, Jun ;

Giobbie-Hurder, Anita ;

Wargo, Jennifer ;

Hodi, F. Stephen .

CLINICAL CANCER RESEARCH, 2013, 19 (03) :598-609

[60] Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression [J].

Jin, Xin ;

Ding, Donglin ;

Yan, Yuqian ;

Li, Hui ;

Wang, Bo ;

Ma, Linlin ;

Ye, Zhenqing ;

Ma, Tao ;

Wu, Qiang ;

Rodrigues, Daniel N. ;

Kohli, Manish ;

Jimenez, Rafael ;

Wang, Liguo ;

Goodrich, David W. ;

de Bono, Johann ;

Dong, Haidong ;

Wu, Heshui ;

Zhu, Runzhi ;

Huang, Haojie .

MOLECULAR CELL, 2019, 73 (01) :22-+

← 1 2 3 4 5 6 7 8 9 10 →